Member Info for Candid

I’ve not been contacted by my broker, my understanding is that in order to facilitate the reverse takeover the shares need to be delisted on AIM while they conclude the deal on ASX.
So following the consolidation, name change, capital raising and deal closing they will trade on ASX and then the company will seek re-admission for trading on AIM (Likely in July). Rules allow shares to be held in an ISA if they are ASX listed and also if they are dual-listed so I don’t see any issue with that, unless there is something different here?

Anyone notice that Thermo Fisher have had their EUA application for PCR testing kit solution approved today.
Not sure how this kit compares to GDR’s but I think this news will reassure some on here that the FDA are still working through EUA’s for PCR testing, particularly ones that will increase throughput and make labs more efficient.

https://www.prnewswire.com/news-releases/fda-authorizes-new-high-throughput-automated-system-for-leading-covid-19-test-301266322.html

Any thoughts why this is still trading much lower than the equivalent listing in Toronto?
Toronto is around 35% higher and has been even more in recent days. Has there been a seller?
I expect this gap to close (conservatively at mid-level), putting CUSN around 10p

The limited series of 50,000 will launch in mid-July, with 40,0000 for general release but pre-orders will be accepted from around April 19th, so likely to get a possible update on this soon. Any thoughts on possible valuations here or will this enter an auction type of sale process?
Also it will be very interesting to learn about the first project Nifty Labs are implementing now, it’s confidential at this point due to commercial sensitivities, but updates can’t be too far away here.

Nice rise in recent days, it doesn’t take much to move with the small volume of shares in issue.
I’m holding but also keeping a fair amount of cash on the side that might be needed once a deal is agreed

On the move today, we may have seen a double bottom here at 1.325p

Gosia,

The press got hold of a draft report few days ago, so it’s not officially published yet but looks like it’s the real deal and the advise is favourable for nuclear.

https://world-nuclear-news.org/Articles/EU-Taxonomy-can-move-forward-with-nuclear-JRC-find

Gosia, It’s probably just a consolidation phase after a good rise in recent weeks. In fact the whole uranium mining sector has given back some gains in recent days. Traders are still moving this sector up and down because they can do so.
Importantly the U308 spot price has had a very good recovery from the $27 levels and in now back over $30 on increasing physical purchases by producers and developers. This activity is likely to be followed by hedge funds, ETFs. The real driver will be utility fuel buyers re-entering both the spot and longterm markets, this will really take off at that stage.
On the risk side, although small as EU are not a big nuclear market, I think some investors and buyers have been waiting to see the EU taxonomy review for nuclear (recommendations for nuclear power to be included as sustainable/green energy investment). Early indications of a draft report (due for release this week) show that the scientific recommendation is in favour of nuclear as a green and sustainable source of energy.

Great to see the spot price at $30.50 to close out last week’s rise.
Fundamentals are looking strong.
EU taxonomy news (expected this week) should provide a further catalyst.

Very pleased with the trial results today, this junior biotech has a very bright future.
FinnCap broker note upped the price target this morning and this is based on just XF-73 alone:
“We have increased our target price from 300p to 370p on the back of the positive Phase 2b data, underpinned by an rNPV of 374p in which we have increased the probability of XF-73 being commercialised from 2025 from 53% to 67%. Our valuation excludes any value attributable to other drugs from the XF platform or SPOR-COV.”

XF-73 study results due by end of March, so could be announced any day over the next 6 trading days. Quietly confident of a positive outcome.

Seems like the M&A strategy is still focused in the Norwegian continental shelf of the North Sea.
More patience is needed but with the share price currently valued at cash levels, you’re getting a proven and experienced oil team for free. A low risk investment with exposure to a significant deal.

Does anybody here know exactly what this new venture is actually trying to do? Have to admit having read recent announcements and listened to the interview I’m still none the wiser. I think Zak was also a bit mystified. “A bridge between crypto and derivatives” does not really explain much, will they enable holders of bitcoin or other tokens to buy shares, corporate bonds etc (instead of buying it directly using cash)? Why would anybody want to do it that way? What are the benefits?
There’s no platform yet and no staff yet creating one, just an idea at the moment.
Major placing a few weeks ago at 1p and now the asking price is 9p.

Should get some indication about strategy and general market conditions for M&A deals from the results tomorrow.
In my opinion I think they are right in being patient until the right deal comes along, there’s no point rushing to close ‘any’ deal and missing out on a much better opportunity.

Anyone with previous experience of the FDA process and if this is significant?
Prior to today there was “awaiting assignment of registration number” for Genedrive on the FDA site. Now there is an Active status with a registration number and FEI number created.

It was probably an algo driven spike this morning, as volume was not huge but nevertheless KAP is starting to get noticed

Interesting price action today, well up this morning and was over $30 at one point.

Today’s RNS has confirmed the results of the test and the next RNS to come very soon will be the launch. I wonder what the commercial value is here? As a speciality test I would think this will attract a premium pricing.
“Our plans to launch the EpiSwitch® Covid-19 Severity Test (CST) based on this groundbreaking biomarker discovery work by the end of Q1 2021, are on track."

Spot price responding strongly now to numerous new physical buyers emerging. Things can get interesting very quickly.

This move by the developers is quite a surprise, but actually a smart move, it will certainly get the alarm bells ringing at utilities fuel buyers. This is probably just the tip of the iceberg, I can see many more entities rushing to buy physical.